Strong global surveillance systems from agencies like the WHO and CDC show no novel pathogen achieving sustained human-to-human transmission or exponential case growth through mid-2026, supporting the 90.5% market-implied odds against a new pandemic. Historical patterns indicate such events remain rare, with current zoonotic threats like avian influenza variants or localized outbreaks contained without meeting pandemic thresholds for widespread geographic spread. Trader consensus reflects this evidence-based stability, though realistic shifts could arise from undetected mutations enabling efficient airborne transmission or a high-impact spillover event during peak respiratory seasons, prompting rapid reassessment as new genomic and epidemiological data emerge.